GENEVA (AP) — Swiss pharmaceutical company Roche Group says it is extending its offer to shareholders of U.S. diagnostics company Illumina Inc. by another month.
Roche has struggled to win over shareholders after Illumina’s board unanimously turned down the Swiss company’s offer of $44.50 per share.
The offer that was supposed to expire March 23 now runs until April 20.
Roche said Monday that all other terms of the $5.7 billion hostile takeover bid, including the price, remain the same.
